TrialSignal
Clinical trial intelligence report
A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00535132
Status
COMPLETED
Phase
PHASE4
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Executive brief
Investment-Ready Snapshot
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00535132
Indication
Schizophrenia
Modality
small molecule
Target
Oral Risperidone, Paliperidone ER
Intervention
Oral Risperidone, Paliperidone ER
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.